• Treatment resistant hypokalemia [ Time Frame: five years ] [ Designated as safety issue: Yes ]
• Stroke [ Time Frame: five years ] [ Designated as safety issue: No ]
• Myocardial infarction [ Time Frame: five years ] [ Designated as safety issue: No ]
• Hospitalization due to heart failure [ Time Frame: five years ] [ Designated as safety issue: No ]
• Arteriosclerosis obliterans (ASO) [ Time Frame: five years ] [ Designated as safety issue: No ]
• Total death [ Time Frame: five years ] [ Designated as safety issue: No ]
• Blood pressure [ Time Frame: five years ] [ Designated as safety issue: No ]
• Lipid profile [ Time Frame: five years ] [ Designated as safety issue: No ]
• HbA1c [ Time Frame: five years ] [ Designated as safety issue: Yes ]
• Fasting blood sugar [ Time Frame: five years ] [ Designated as safety issue: Yes ]
• Cost [ Time Frame: five years ] [ Designated as safety issue: No ]
• Gout [ Time Frame: five years ] [ Designated as safety issue: Yes ]

• Gout
• Treatment resistant hypokalemia
• Stroke
• Myocardial infarction
• Hospitalization due to heart failure
• ASO
• Total death
• Blood pressure
• Lipid profile
• HbA1c
• Fasting blood sugar
• Cost

The purpose of DIME is to evaluate the safety (i.e. new onset of diabetes and other metabolic adverse events), efficacy and cost-effectiveness of antihypertensive treatment with low dose diuretics. The researchers' hypothesis is that use of low dose thiazide diuretics is metabolically safe when used with other appropriate antihypertensives, effective in reduction of blood pressure and cheaper than treatment without diuretics. Therefore, this study is an equivalence trial.

There has been substantial evidence from clinical trials to support the rationale of use of thiazide diuretics in patients with essential hypertension. Diuretics may be more effective in reduction of blood pressure in Japanese patients than Caucasian because of higher salt intake. Moreover, given a large number of hypertensive population here, diuretics may be the most cost-effective antihypertensive agent. Japanese physicians, however, tend to avoid diuretics even in elderly hypertensive patients because of much concern over metabolic adverse events including new onset diabetes, which is deemed to increase cardiovascular risk. Although it is unlikely that use of low dose (12.5 mg of HCTZ or less) diuretics is associated with metabolic adverse events when they are given with any other appropriate antihypertensive agents (e.g. Ca antagonist, ACE inhibitor, ARB, K sparing diuretics) other than β-blockers, the researchers have to confirm the safety of low dose diuretics in terms of new onset diabetes in Japanese, who are assumed to be "diabetes prone" based upon thrifty gene hypothesis.

• Drug: Thiazide diuretics
• Drug: No diuretics

• Active Comparator: Diuretics use
• Active Comparator: No diuretics use

Inclusion Criteria:

• Aged 30 to 79 years
• With blood pressure being >150/>90 if they are not on any antihypertensive treatment
• With blood pressure being >140/>90 if they are already on antihypertensive drugs
• No history of type 2 diabetes
• No history of gout

Exclusion Criteria:

• With supine blood pressure being >200/>120
• Patients already on antihypertensive treatment if duration of treatment and drugs used are not identified
• Patients already on thiazide diuretics
• With type 2 diabetes
• With gout or hyperuricaemia (>8.0 mg/dl)
• With hypokalemia（<3.5mmol/L）
• With erectile dysfunction
• With renal dysfunction (s-creatinine > 2.0 mg/dL)
• With history of serious adverse reaction to thiazide diuretics
• With history of stroke or myocardial infarction within 6 months
• With history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within 6 months or in whom these interventions are planned
• With heart failure or left ventricular dysfunction (ejection fraction<40%)
• Patients who should be on thiazide diuretics
• With history of malignant tumor within 5 years
• Pregnant, possibility of pregnancy, or during breast feeding
• Patients who are deemed not eligible for this study for any reason